EyePoint, Inc.

Healthcare · Biotechnology · United States

Last price 0.38 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 32.76M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ...